By ANDY OBER
InsideINdianaBusiness

INDIANAPOLIS — Indianapolis-based Eli Lilly and Co. says the diabetes treatment Jardiance met its primary endpoint in a latest clinical trial. The company says the treatment lowered cardiovascular risk in adults with type 2 diabetes.

Lilly says the long-term trial involved more than 7,000 patients from 42 countries. at high risk for cardiovascular events.

Jardiance was developed by Lilly and Boehringer Ingelheim Corp. The U.S. Food and Drug Administration approved the treatment last year for use in improving blood glucose levels.

Lilly says it will present the study findings next month at the 51st European Association for the Study of Diabetes Annual Meeting in Sweden.